Financhill
Sell
28

BIOLQ Quote, Financials, Valuation and Earnings

Last price:
$0.0100
Seasonality move :
-2.06%
Day range:
$0.0123 - $0.0130
52-week range:
$0.0040 - $0.2000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.01x
P/B ratio:
--
Volume:
8K
Avg. volume:
64.1K
1-year change:
-91.01%
Market cap:
$475.8K
Revenue:
$49.2M
EPS (TTM):
-$2.04

Analysts' Opinion

  • Consensus Rating
    Biolase has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $1.2000, Biolase has an estimated upside of 15284.62% from its current price of $0.0130.
  • Price Target Downside
    According to analysts, the lowest downside price target is $0.4000 representing 100% downside risk from its current price of $0.0130.

Fair Value

  • According to the consensus of 2 analysts, Biolase has 15284.62% upside to fair value with a price target of $1.2000 per share.

BIOLQ vs. S&P 500

  • Over the past 5 trading days, Biolase has overperformed the S&P 500 by 28.17% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Biolase does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Biolase revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Biolase reported revenues of $10.9M.

Earnings Growth

  • Biolase has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Biolase reported earnings per share of -$0.04.
Enterprise value:
14.7M
EV / Invested capital:
--
Price / LTM sales:
0.01x
EV / EBIT:
--
EV / Revenue:
0.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$15.9M
Return On Assets:
-48.28%
Net Income Margin (TTM):
-34.84%
Return On Equity:
-21668.17%
Return On Invested Capital:
-129.74%
Operating Margin:
-6.41%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $46.8M $49.7M $46M $10.9M $10.9M
Gross Profit $17.2M $16.8M $15.9M $3.7M $4.4M
Operating Income -$21.2M -$21.3M -$13.5M -$3.7M -$695K
EBITDA -$21.7M -$19.6M -$11M -$3.4M -$166K
Diluted EPS -$358.34 -$182.32 -$2.04 -$10.35 -$0.04
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $36M $52.7M $33.9M $27.8M $19.4M
Total Assets $42M $58.5M $42.9M $38.7M $27.2M
Current Liabilities $21.4M $13.5M $13.8M $19.8M $30.9M
Total Liabilities $28.1M $28.2M $29M $38.4M $32.5M
Total Equity $13.9M $30.3M $13.9M $332K -$5.2M
Total Debt $16.1M $13.5M $12.8M $14.1M $17.6M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$24.3M -$17.4M -$13.4M -$2.6M -$4.5M
Cash From Investing -$3.6M -$1.6M $288K -$182K $34K
Cash From Financing $4.7M $16.5M $8.6M $3.8M $2.5M
Free Cash Flow -$27.9M -$19M -$13.7M -$2.8M -$4.5M
BIOLQ
Sector
Market Cap
$475.8K
$35.2M
Price % of 52-Week High
6.5%
44.63%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-91.01%
-39.07%
Beta (5-Year)
0.016
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $0.0116
200-day SMA
Sell
Level $0.0247
Bollinger Bands (100)
Buy
Level 0.0097 - 0.0097
Chaikin Money Flow
Sell
Level -348.1M
20-day SMA
Buy
Level $0.0119
Relative Strength Index (RSI14)
Buy
Level 55.6970
ADX Line
Buy
Level 56.8236
Williams %R
Neutral
Level -42.2535
50-day SMA
Buy
Level $0.0102
MACD (12, 26)
Buy
Level 0.0005
25-day Aroon Oscillator
Buy
Level 72
On Balance Volume
Neutral
Level 841.2M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-12.7069)
Sell
CA Score (Annual)
Level (-4.1866)
Buy
Beneish M-Score (Annual)
Level (-3.4791)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.4)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (1)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Stock Forecast FAQ

In the current month, BIOLQ has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BIOLQ average analyst price target in the past 3 months is $1.2000.

  • Where Will Biolase Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Biolase share price will rise to $1.2000 per share over the next 12 months.

  • What Do Analysts Say About Biolase?

    Analysts are divided on their view about Biolase share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biolase is a Sell and believe this share price will drop from its current level to $0.4000.

  • What Is Biolase's Price Target?

    The price target for Biolase over the next 1-year time period is forecast to be $1.2000 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is BIOLQ A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Biolase is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.

  • How Can I Buy Shares Of BIOLQ?

    You can purchase shares of Biolase via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biolase shares.

  • What Is The Biolase Share Price Today?

    Biolase was last trading at $0.0100 per share. This represents the most recent stock quote for Biolase. Yesterday, Biolase closed at $0.0130 per share.

  • How To Buy Biolase Stock Online?

    In order to purchase Biolase stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is down 19.47% over the past day.

Buy
65
MYRG alert for May 2

MYR Group [MYRG] is up 1.79% over the past day.

Sell
35
FTAI alert for May 2

FTAI Aviation [FTAI] is up 5.77% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock